<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047004</url>
  </required_header>
  <id_info>
    <org_study_id>PIPAC-OPC4</org_study_id>
    <nct_id>NCT04047004</nct_id>
  </id_info>
  <brief_title>Adjuvant PIPAC in Gastric Cancer Patients</brief_title>
  <acronym>PIPAC-OPC4</acronym>
  <official_title>Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) During Laparoscopic Resection in High-risk Gastric Cancer Patients: A Multicentre Phase-I Study (the PIPAC-OPC4 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Bau Mortensen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study patients will be offered intraperitoneal atomized chemotherapy as a supplement
      to the standard treatment of high-risk gastric cancer (laparoscopic removal of the stomach).
      Two commercially available oncologic drugs will be used (doxorubicin and cisplatin).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric adenocarcinoma (GAC) is considered the fifth most common cancer in the word and the
      third leading cause of cancer death globally. The majority of GAC patients presents with
      advanced stages of disease leading to a dismal prognosis even after treatments with curative
      intent.

      Irrespective of these tumors' origin, the peritoneum is one of the most frequent sites of
      metastases and recurrences that generally determines the subsequent prognosis. Additionally,
      it is observed that none of the currently available perioperative chemotherapy regimens have
      been able to reduce the risk for peritoneal deposits. Peritoneal metastases (PMs) are formed
      during processes that entraps the malignant cells and this restrictive milieu is thought to
      hinder the penetrance of drugs delivered systemically and provides grounds for the early
      administration of intraperitoneal treatments. The presence of malignant intraperitoneal cells
      that is not cleared by chemotherapy before surgery, and/or seeding of malignant cells during
      surgery, are probably the major reasons for the development of PM and thus the poor prognosis
      after seemingly micro-radical surgery.

      Since only a fraction of the systemically administered chemotherapy reaches the peritoneum,
      the effect of intraperitoneal chemotherapy has been eagerly studied. A recent systematic
      review and meta-analysis identified three trials evaluating the effect of intraperitoneal
      chemotherapy and/or extensive peritoneal lavage in gastric cancer patients who underwent
      subsequent surgery. Two and five-year overall survival increased significantly in patients
      who had intraperitoneal chemotherapy (RR=1.62 and 3.10) and survival further increased by the
      addition of extensive lavage (RR= 2.33 and 6.19).

      The intraperitoneal delivery and subsequent uptake of chemotherapy is improved by a new
      aerosol technique. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) has shown
      promising results in patients with PM from colorectal, ovarian and gastric cancer (see
      below), and PIPAC is feasible, safe and well tolerated by the majority of patients. Our own
      database assessed the outcome of PIPAC, with low-dose cisplatin and doxorubicin, in GAC
      patients with chemotherapy-resistant PM. Objective tumor response was documented in 40% of
      the patients after PIPAC, including complete histological regression in some, whereas an
      additional 20% had no further tumor progression (manuscript in preparation). These
      observations in GAC patients deliver further evidence suggesting that PIPAC can induce
      regression of resistant PMs in several cancer types and might meet the clinical need for new
      and better therapies for fatal cancer disease states. Our results also provide evidence that
      low-dose PIPAC therapy might be effective in treating patients with recurrent,
      chemo-resistant gastric PMs, including the aggressive signet-ring histology.

      The imminent question is whether PIPAC delivered immediately after a laparoscopic gastrectomy
      for GAC, in patients being exposed to a significant risk of early recurrent disease, can be
      safely carried out? If so, for the first time, a corresponding therapeutic concept can be
      offered to similar GAC patients in addition to surgery with curative intent. This could
      potentially increase progression free and eventually overall survival.

      Twenty patients will be enrolled from two Danish and Swedish hospitals according to the
      inclusion and exclusion criteria and included in the data analysis if laparoscopic removal of
      the stomach and subsequent immediate PIPAC has been performed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, multicenter, non-randomized, non-blinded, open-label</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Medical adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>According to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>30 days</time_frame>
    <description>According to the Dindo-Clavien classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>The amount of time the patient is hospitalized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive peritoneal lavage</measure>
    <time_frame>30 days</time_frame>
    <description>The rate of positive peritoneal lavage before and after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjuvant chemotherapy</measure>
    <time_frame>30 days</time_frame>
    <description>The number of patients that receive adjuvant systemic chemotherapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>High-risk gastric cancer patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study population of high-risk gastric cancer patients will be offered one session of PIPAC immediately after laparoscopic removal of the stomach.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Conventional PIPAC with doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.</description>
    <arm_group_label>High-risk gastric cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Conventional PIPAC with cisplatin (10.5 mg/m2 body surface in 150ml saline) is performed through the CE-certified nebulizer by certified PIPAC surgeons directly after the completion of the laparoscopic gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is installed at a rate of 0.5-0.8 ml/s with a maximum pressure of 300 pressure per square inch and 30 minutes of simple diffusion.</description>
    <arm_group_label>High-risk gastric cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with high-risk GAC defined as: Diffuse cancer (signet ring cells predominant)
             or clinical stage: cTany + cN2-3 or cT3-T4 + cNany or GAC patients with preoperative
             positive peritoneal cytology submitted to laparoscopic gastrectomy (+/- neoadjuvant
             treatment).

          -  Age 18 or above

          -  Written informed consent

          -  Women must be postmenopausal or use adequate contraception with a negative pregnancy
             test at inclusion.

        Exclusion Criteria:

          -  Previous allergic reaction to cisplatin, doxorubicin or other platinum containing
             compounds.

          -  Renal impairment, defined as GFR &lt; 40 ml/min (Cockcroft-Gault Equation).

          -  Myocardial insufficiency, defined as NYHA class 3-4.

          -  Impaired liver function defined as bilirubin ≥ 1.5 x UNL (upper normal limit).

          -  Inadequate haematological function defined as absolute neutrophil count (ANC) ≤ 1.5 x
             10^9/l and platelets ≤ 100 x 10^9/l.

          -  Any other condition or therapy, which in the investigator's opinion may pose a risk to
             the patient or interfere with the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Signe Bremholm Ellebæk, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Signe Bremholm Ellebæk, MD, PhD</last_name>
    <phone>004565415190</phone>
    <email>Signe.Bremholm.Ellebaek@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Bau Mortensen, Professor</last_name>
    <phone>004529694638</phone>
    <email>michael.bau.mortensen@rsyd.dk</email>
  </overall_contact_backup>
  <reference>
    <citation>Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ. Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011 Jun;2(2):77-84. doi: 10.3978/j.issn.2078-6891.2010.025.</citation>
    <PMID>22811834</PMID>
  </reference>
  <reference>
    <citation>Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064. doi: 10.1002/14651858.CD004064.pub4. Review.</citation>
    <PMID>28850174</PMID>
  </reference>
  <reference>
    <citation>Al-Batran SE, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, Schmalenberg H, Luley KB, Prasnikar N, Egger M, Probst S, Messmann H, Moehler M, Fischbach W, Hartmann JT, Mayer F, Höffkes HG, Koenigsmann M, Arnold D, Kraus TW, Grimm K, Berkhoff S, Post S, Jäger E, Bechstein W, Ronellenfitsch U, Mönig S, Hofheinz RD. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017 Sep 1;3(9):1237-1244. doi: 10.1001/jamaoncol.2017.0515.</citation>
    <PMID>28448662</PMID>
  </reference>
  <reference>
    <citation>Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Dec;17(12):1697-1708. doi: 10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22.</citation>
    <PMID>27776843</PMID>
  </reference>
  <reference>
    <citation>Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20.</citation>
    <PMID>16822992</PMID>
  </reference>
  <reference>
    <citation>Bringeland EA, Wasmuth HH, Grønbech JE. Perioperative chemotherapy for resectable gastric cancer - what is the evidence? Scand J Gastroenterol. 2017 Jun - Jul;52(6-7):647-653. doi: 10.1080/00365521.2017.1293727. Epub 2017 Feb 28. Review.</citation>
    <PMID>28276825</PMID>
  </reference>
  <reference>
    <citation>Takebayashi K, Murata S, Yamamoto H, Ishida M, Yamaguchi T, Kojima M, Shimizu T, Shiomi H, Sonoda H, Naka S, Mekata E, Okabe H, Tani T. Surgery-induced peritoneal cancer cells in patients who have undergone curative gastrectomy for gastric cancer. Ann Surg Oncol. 2014 Jun;21(6):1991-7. doi: 10.1245/s10434-014-3525-9. Epub 2014 Feb 6.</citation>
    <PMID>24499832</PMID>
  </reference>
  <reference>
    <citation>De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol. 2014 Sep;110(3):291-7. doi: 10.1002/jso.23632. Epub 2014 May 22. Review.</citation>
    <PMID>24850538</PMID>
  </reference>
  <reference>
    <citation>Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006 Aug;6(8):583-92. Review.</citation>
    <PMID>16862189</PMID>
  </reference>
  <reference>
    <citation>Bentrem D, Wilton A, Mazumdar M, Brennan M, Coit D. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol. 2005 May;12(5):347-53. Epub 2005 Mar 31.</citation>
    <PMID>15915368</PMID>
  </reference>
  <reference>
    <citation>Ji ZH, Peng KW, Li Y. Intraperitoneal free cancer cells in gastric cancer: pathology of peritoneal carcinomatosis and rationale for intraperitoneal chemotherapy/hyperthermic intraperitoneal chemotherapy in gastric cancer. Transl Gastroenterol Hepatol. 2016 Sep 19;1:69. doi: 10.21037/tgh.2016.08.03. eCollection 2016. Review.</citation>
    <PMID>28138635</PMID>
  </reference>
  <reference>
    <citation>Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, Ceresoli M, Montori G, Ansaloni L. Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta-analysis. Eur J Surg Oncol. 2016 Sep;42(9):1261-7. doi: 10.1016/j.ejso.2016.03.035. Epub 2016 Apr 19. Review.</citation>
    <PMID>27134147</PMID>
  </reference>
  <reference>
    <citation>Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, Hübner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. Br J Surg. 2017 May;104(6):669-678. doi: 10.1002/bjs.10521. Review.</citation>
    <PMID>28407227</PMID>
  </reference>
  <reference>
    <citation>Graversen M, Lundell L, Fristrup C, Pfeiffer P, Mortensen MB. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) as an outpatient procedure. Pleura Peritoneum. 2018 Nov 27;3(4):20180128. doi: 10.1515/pp-2018-0128. eCollection 2018 Dec 1.</citation>
    <PMID>30911669</PMID>
  </reference>
  <reference>
    <citation>Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol. 2018 Jun 1;10:1758835918777036. doi: 10.1177/1758835918777036. eCollection 2018.</citation>
    <PMID>29899763</PMID>
  </reference>
  <reference>
    <citation>Graversen M, Pedersen PB, Mortensen MB. Environmental safety during the administration of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Pleura Peritoneum. 2016 Dec 1;1(4):203-208. doi: 10.1515/pp-2016-0019. Epub 2016 Nov 25.</citation>
    <PMID>30911624</PMID>
  </reference>
  <reference>
    <citation>Graversen M, Fristrup C, Kristensen TK, Larsen TR, Pfeiffer P, Mortensen MB, Detlefsen S. Detection of free intraperitoneal tumour cells in peritoneal lavage fluid from patients with peritoneal metastasis before and after treatment with pressurised intraperitoneal aerosol chemotherapy (PIPAC). J Clin Pathol. 2019 May;72(5):368-372. doi: 10.1136/jclinpath-2018-205683. Epub 2019 Feb 12.</citation>
    <PMID>30755498</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Michael Bau Mortensen</investigator_full_name>
    <investigator_title>Professor, Consultant, DMSci, PhD, MD</investigator_title>
  </responsible_party>
  <keyword>Gastric adenocarcinoma</keyword>
  <keyword>Intraperitoneal chemotherapy</keyword>
  <keyword>Laparoscopic gastrectomy</keyword>
  <keyword>Gastric cancer</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

